Latest Breaking News On - Biosciences investor contact - Page 6 : comparemela.com

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS ON OCTOBER 31, 2023

PLYMOUTH MEETING, Pa., Oct. 17, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients.

Luis sanayParagon biosciencesPrnewswire harmony biosciences holdings incCompany nasdaqBiosciences holdingsHarmony biosciencesPlymouth meetingBiosciences investor contactBiosciences media contact

HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and.

United statesKumar budurLuis sanayDrug administrationPrnewswire harmony biosciences holdings incCompany nasdaqParagon biosciencesExchange commissionBiosciences holdingsChief medical officerHarmony biosciencesEpworth sleepiness scaleCall todayFull prescribing informationPlymouth meetingPrivate securities litigation reform act

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - Zynerba

Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2.

United kingdomUnited statesNew yorkLuis sanayJeffreym daynoExchange commissionEuropean medicines agencyDrug administrationParagon biosciencesEuropean unionHarmony biosciences holdings incZynerba pharmaceuticals incBiosciences holdingsStates foodMedicines agencyYork city

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew yorkUnited statesJeffreym daynoLuis sanayExchange commissionEuropean medicines agencyHarmony biosciences holdings incZynerba pharmaceuticals incDrug administrationParagon biosciencesEuropean unionHarmony biosciences holdingsZynerba pharmaceuticalsUnited states foodNew york city

HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and.

United statesKumar budurLuis sanayParagon biosciencesFoundation for prader willi researchExchange commissionPrnewswire harmony biosciences holdings incDrug administrationCompany nasdaqBiosciences holdingsPrader willi researchAberrant behavioralChief medical officerSecondary outcomesPlacebo controlled signal detectionProof of concept study